dovepress
submit
manuscript
wwwdovepresscom
dovepress
r
g
n
l
r
e
e
r
c
h
open
access
scientif
medic
research
open
access
full
text
articl
peopl
republ
china
shandong
provinci
key
laboratori
carbohydr
chemistri
glycobiolog
shandong
univers
jinan
shandong
peopl
republ
china
school
pharmaceut
scienc
shandong
univers
jinan
shandong
peopl
republ
china
author
contribut
equal
work
past
year
signific
progress
made
inhibit
neovascular
tumor
site
cut
nutrient
suppli
tumor
inhibit
tumor
growth
metastasi
howev
mani
proteinspeptid
disadvantag
poor
stabil
short
halflif
uncertain
target
abil
chemic
modif
use
overcom
disadvantag
mani
polyethylen
glycolmodifi
proteinspeptid
approv
us
fda
purpos
studi
obtain
novel
antiangiogen
chondroitin
sulfat
cs
peptid
nanoparticl
conjug
effici
antineovascular
tumor
target
abil
accept
halflif
nanoparticl
conjug
synthes
character
use
hnuclear
magnet
reson
spectroscopi
transmiss
electron
microscopi
particl
size
zeta
potenti
analyz
antiangiogen
abil
studi
use
mtt
migrat
tube
format
chick
chorioallanto
membran
assay
target
abil
studi
elisa
surfac
plasmon
reson
bioimag
pharmacokinet
also
studi
result
could
selfassembl
stabl
nanoparticl
aqueou
solut
significantli
enhanc
antineovascular
activ
tumor
target
explicit
prolong
halflif
conclus
cs
effect
proteinpeptid
modifi
display
good
potenti
tumor
target
therapi
chondroitin
sulfat
cs
glycosaminoglycan
compos
altern
dglucuron
acid
nacetyldgalactosamin
residu
wide
present
extracellular
matrix
cell
surfac
anim
tissu
particularli
abund
cartilag
tissu
endogen
mucopolysaccharid
good
histocompat
often
use
drug
modif
construct
drug
carrier
csmodifi
cisplatin
display
improv
anticanc
activ
reduc
drug
toxic
csmodifi
glucocorticoid
prolong
releas
time
drug
vivo
enhanc
efficaci
without
toxic
side
effect
addit
cs
also
ligand
specif
target
tumor
cell
short
peptid
contain
eleven
amino
acid
ivrradraavp
main
activ
fragment
endostatin
es
antiangiogen
properti
studi
bioactiv
found
could
effect
inhibit
prolifer
migrat
endotheli
cell
hexapeptid
gnqwfi
af
centrifug
tube
purchas
corn
inc
new
york
ny
usa
dimethyl
sulphoxid
dmso
tetrabutylammonium
hydroxid
tba
purchas
sinopharm
chemic
reagent
co
ltd
shanghai
china
tri
dimethylamino
phosphonium
hexafluorophosph
bop
purchas
tci
co
ltd
shanghai
china
fluorescein
isothiocyan
fitc
purchas
shanghai
purpl
one
reagent
factori
shanghai
china
vegf
basic
fibroblast
growth
factor
bfgf
purchas
peprotech
rocki
hill
nj
usa
tween
color
liquid
purchas
beyotim
biolog
technolog
co
ltd
shanghai
china
antihuman
igghrpfc
purchas
cusabio
biolog
engin
co
ltd
wuhan
china
recombin
protein
fltfc
purchas
r
system
minneapoli
mn
usa
chemic
reagent
highest
commerci
grade
avail
cstba
prepar
accord
previous
describ
protocol
cstba
dissolv
dmso
bop
g
ad
mix
minut
activ
carboxyl
group
cstba
peptid
mg
dissolv
dmso
ad
reaction
solut
final
dipea
ad
reaction
solut
mix
hour
equal
volum
nacl
aqueou
solut
ad
reaction
solut
ph
adjust
hcl
termin
reaction
ph
rais
naoh
result
solut
dialyz
dialysi
bag
kda
molecular
weight
cutoff
subsequ
freezedri
structur
obtain
determin
hnmr
store
analysi
morpholog
observ
tem
sampl
mg
dissolv
ml
distil
water
stain
aqueou
solut
phosphotungst
acid
allow
dri
observ
microscop
solut
mgml
prepar
deioniz
water
size
distribut
zeta
potenti
result
solut
determin
use
particl
size
zeta
potenti
analyz
experi
perform
cell
obtain
shanghai
cell
bank
institut
cell
xing
et
al
biolog
china
academi
scienc
shanghai
china
cell
cultiv
dmem
supplement
fb
penicillinstreptomycin
incub
co
humidifi
atmospher
cell
cultur
condit
rpmi
medium
cell
subcultur
confluenc
toxic
evalu
use
mtt
assay
dehydrogenas
present
mitochondria
live
cell
reduc
mtt
cell
seed
plate
densiti
cell
per
well
treat
variou
concentr
concentr
refer
portion
hour
incub
media
remov
mtt
solut
ad
well
follow
incub
hour
dark
supernat
remov
dmso
ad
well
gentli
shaken
minut
complet
dissolv
precipit
micropl
reader
use
measur
absorb
dissolv
precipit
nm
inhibit
rate
ir
calcul
accord
formula
woundheal
assay
cell
seed
onto
sixwel
plate
treat
differ
concentr
concentr
refer
portion
hour
three
parallel
cellfre
gap
creat
well
pipett
tip
imag
taken
use
invert
fluoresc
microscop
cell
migrat
wound
area
calcul
tube
format
assay
cell
propag
dmem
supplement
fb
cell
well
seed
onto
plate
coat
matrigel
follow
treatment
dmem
contain
differ
concentr
concentr
refer
portion
bfgf
ad
well
made
final
concentr
ngml
peak
tube
format
observ
hour
cultur
five
random
field
observ
microscop
number
branch
per
field
tube
treatment
quantifi
experi
independ
repeat
five
time
cam
assay
chicken
embryo
commonli
use
model
detect
antiangiogen
inhibitor
therefor
use
cam
assay
determin
effect
neovascular
forti
welldevelop
chicken
embryo
place
steril
incub
rel
humid
steril
environ
larg
end
chicken
embryo
wipe
iodin
alcohol
small
hole
made
top
chicken
embryo
upper
air
chamber
membran
peel
lower
cam
membran
expos
place
incub
incub
hour
gelatin
spong
cm
diamet
use
load
carrier
place
chicken
embryo
allanto
membran
concentr
refer
portion
separ
ad
gelatin
spong
blank
control
salin
volum
group
group
three
chicken
embryo
xing
et
al
chip
activ
activ
reagent
protein
ad
final
chip
block
ethanolaminehcl
solut
final
affin
kinet
data
test
singleloop
experi
accord
wizard
program
oper
system
affin
two
drug
compar
bioimag
fitclabel
conjug
studi
target
properti
modifi
product
label
fitc
accord
previou
protocol
tumor
model
establish
subcutan
inject
cell
ml
right
armpit
nude
mous
approv
number
ethic
committe
tumor
volum
reach
approxim
mm
nude
mice
inject
fitclabel
compound
cs
via
tail
vein
anim
experi
studi
approv
ethic
committe
school
nurs
shandong
univers
perform
follow
ethic
guidelin
care
use
anim
salin
use
control
dose
experiment
group
mgkg
concentr
refer
portion
vivo
imag
system
kinet
system
use
visual
nude
mice
hour
administr
distribut
drug
observ
mice
time
point
pharmacokinet
studi
balbc
mice
g
fast
hour
randomli
divid
three
group
inject
via
tail
vein
peptid
dose
mgkg
concentr
refer
portion
blood
sampl
collect
fundu
venou
plexu
hour
administr
sampl
allow
stand
hour
supernat
collect
centrifug
minut
equal
volum
sd
solut
ad
supernat
fluoresc
sensit
final
fluoresc
intens
sampl
measur
fluoresc
spectrophotomet
excit
nm
emiss
nm
result
synthesi
conjug
polypeptid
synthes
solidphas
peptid
synthesi
analyz
highperform
liquid
chromatographi
puriti
polypeptid
retent
time
min
molecular
weight
polypeptid
measur
mass
spectrometri
ms
improv
solubl
cs
organ
solvent
cs
modifi
use
tbaoh
form
dmsosolubl
conjug
cstba
yield
cstba
hnmr
spectrum
cstba
shown
figur
compar
hnmr
spectra
cs
figur
show
four
signal
peak
chemic
shift
ppm
ppm
ppm
ppm
characterist
peak
butyl
group
reactant
tbaoh
signal
peak
rang
ppm
correspond
characterist
methyl
group
peak
acetylamino
group
cs
hnmr
spectra
product
show
conjug
cstba
success
prepar
ion
exchang
good
solubl
dmso
conjug
prepar
yield
approxim
figur
hnmr
spectrum
shown
figur
compar
figur
figur
found
besid
cs
signal
peak
signal
peak
also
found
figur
obtain
spectra
peak
ppm
correspond
aromat
ring
phenylalanin
tryptophan
peak
ppm
correspond
methyl
reson
acetamido
moieti
cs
compar
peak
ppm
peak
ppm
determin
peptid
content
success
conjug
cs
novel
angiogen
peptid
confirm
hnmr
spectroscopi
prepar
contain
two
peptid
molecul
per
cs
chain
tem
imag
figur
show
particl
uniform
nanos
sphere
averag
size
particl
nm
nm
respect
figur
small
particl
size
well
uniform
size
distribut
nanoparticl
suitabl
develop
nanomedicin
zeta
potenti
mv
mv
respect
indic
conjug
cs
enhanc
stabil
system
base
result
conclud
selfassembl
wellstabil
nanoparticl
aqueou
solut
structur
enabl
peptid
encapsul
csform
nanoparticl
xing
et
al
avoid
loss
activ
caus
proteas
hydrolysi
studi
shown
cs
specif
bind
surfac
tumor
cell
presenc
nanoparticl
enabl
cs
act
target
vector
carri
surfac
tumor
cell
therebi
indic
play
better
role
antiangiogenesi
inhibitori
effect
prolifer
endotheli
cell
measur
mtt
assay
shown
figur
concentr
ir
endotheli
cell
respect
result
seen
ir
cell
show
concentrationdepend
effect
rang
inhibitori
rate
similar
indic
activ
similar
rel
low
concentr
concentr
increas
ir
higher
concentr
indic
activ
significantli
better
high
concentr
activ
polypeptid
drug
often
relat
structur
compar
small
molecul
drug
polypeptid
drug
often
poor
aqueou
stabil
due
spatial
structur
antiangiogen
peptid
modifi
cs
stabil
conjug
aqueou
solut
improv
due
fact
cs
group
aqueou
solut
forc
water
molecul
around
polypeptid
enhanc
stabil
therefor
infer
higher
concentr
cs
better
stabil
addit
result
mtt
assay
also
relat
state
endotheli
cell
degre
differenti
therefor
mtt
assay
use
evalu
inhibitori
effect
drug
endotheli
cell
prolifer
cell
similar
passag
number
select
experi
cell
migrat
assay
cell
cocultur
cell
cultur
medium
contain
differ
concentr
cs
hour
photograph
fluoresc
microscop
obtain
graph
cell
migrat
initi
posit
scratch
mark
black
solid
line
figur
shown
figur
differ
sampl
concentr
activ
higher
activ
concentr
effect
endotheli
cell
migrat
significantli
better
like
mtt
assay
result
even
concentr
rel
low
cs
could
improv
solubl
cs
could
increas
number
water
molecul
near
increas
stabil
thu
could
inhibit
endotheli
cell
metastasi
effici
concentr
increas
inhibitori
effect
endotheli
cell
similar
thu
cs
could
promot
adhes
growth
endotheli
cell
certain
extent
counteract
inhibitori
effect
tube
format
assay
use
investig
effect
cs
blood
vessel
format
cell
number
tube
repres
number
branchesfield
differ
concentr
drug
ad
plate
incub
hour
plate
photograph
fluoresc
microscop
figur
tube
format
endotheli
cell
could
observ
figur
larg
number
tube
form
control
group
incub
hour
compar
control
group
number
tube
form
lowconcentr
experiment
group
less
indic
low
concentr
drug
could
also
inhibit
endotheli
cell
tube
format
concentr
increas
number
tube
branchesfield
group
significantli
reduc
cell
isol
tube
branchesfield
still
visibl
group
process
data
figur
found
number
tube
form
control
group
tradit
cam
test
use
studi
effect
drug
angiogenesi
vivo
antiangiogen
abil
drug
express
percentag
neovascular
stereoscop
microscop
cam
vascular
network
control
group
show
clear
veinlik
distribut
addit
physiolog
salin
bfgf
figur
number
small
vessel
gener
around
main
vessel
increas
small
blood
vessel
grew
exuberantli
produc
branch
therebi
increas
densiti
whole
blood
vessel
field
within
drug
group
densiti
blood
vessel
decreas
significantli
concentr
drug
increas
show
activ
cam
posit
correl
concentr
concentr
activ
cs
mixtur
group
slightli
less
two
group
chemic
modifi
product
smallest
number
small
blood
vessel
around
main
blood
vessel
almost
visibl
small
blood
vessel
exist
field
view
stereoscop
corrobor
result
newli
gener
vessel
group
statist
analyz
figur
drug
treatment
hour
neovascular
rate
control
group
concentr
drug
neovascular
rate
group
respect
concentr
proport
new
vessel
cs
group
respect
compar
group
found
concentr
signific
differ
activ
modifi
product
concentr
activ
lower
unmodifi
polypeptid
might
due
watersolubl
cs
form
gellik
barrier
near
low
concentr
affect
contact
chicken
embryo
therebi
reduc
effect
make
conjug
less
activ
low
concentr
concentr
activ
higher
unmodifi
polypeptid
might
due
increas
stabil
vivo
therebi
improv
activ
inhibitori
effect
bind
capac
vegf
receptor
determin
elisa
absorb
posit
control
well
set
ratio
experiment
well
contrast
well
absorpt
valu
use
express
inhibitori
abil
differ
experiment
sampl
shown
figur
inhibitori
abil
three
experiment
group
increas
significantli
increas
concentr
rang
indic
inhibit
occur
concentrationdepend
manner
concentr
inhibit
significantli
better
cs
indic
glycosyl
modif
significantli
enhanc
abil
inhibit
bind
vegf
consist
cell
prolifer
experiment
result
mention
earlier
studi
activ
fragment
af
inhibit
bind
vegf
receptor
af
peptid
contain
sever
aromat
amino
acid
poor
water
solubl
peptid
watersolubl
mucopolysaccharid
cs
use
modifi
af
result
modifi
product
improv
water
solubl
thu
inhibit
bind
vegf
receptor
better
addit
glycosyl
could
also
increas
stabil
aqueou
solut
compar
unmodifi
modifi
stabl
thu
show
better
inhibit
result
could
also
verifi
cam
experi
ph
valu
suitabl
coupl
reaction
screen
preenrich
experi
ensur
suffici
protein
coupl
onto
chip
facilit
next
screen
drug
experiment
result
show
ph
valu
protein
solut
respons
valu
proteinchip
bind
highest
ph
thu
taken
ideal
ligand
coupl
condit
figur
ligand
conjug
perform
condit
concentr
coupl
protein
solut
final
protein
coupl
amount
ru
flow
chip
gener
dynam
sens
fit
plot
affin
kinet
paramet
k
l
mol
k
interact
protein
respect
k
bind
constant
sampl
k
dissoci
constant
sampl
kd
k
k
equilibrium
dissoci
constant
use
measur
abil
interact
sampl
smaller
kd
valu
stronger
affin
sampl
kd
valu
figur
kd
valu
much
smaller
figur
indic
bind
affin
csmodifi
glycosyl
polypeptid
receptor
better
affin
unmodifi
polypeptid
gener
k
valu
rang
indic
strong
sampletoligand
affin
accord
result
present
affin
polypeptid
receptor
weak
cs
ligand
receptor
bind
specif
receptor
therefor
affin
cs
receptor
theoret
stronger
unmodifi
could
conclud
cs
could
increas
target
drug
tumor
tissu
nude
mice
bear
melanoma
randomli
divid
two
group
tumor
volum
reach
mm
administ
tail
vein
nude
mice
anesthet
intraperiton
inject
chloral
hydrat
nude
mice
stabl
anesthesia
photograph
live
imag
record
vivo
bioimag
differ
time
point
shown
figur
fluoresc
observ
group
mice
hour
indic
mice
fluoresc
interfer
fluoresc
captur
vivo
bioimag
drug
distribut
within
mice
distribut
metabol
drug
nude
mice
follow
hour
distribut
throughout
whole
bodi
nude
mice
fluoresc
appear
tumor
signific
differ
fluoresc
intens
tumor
cell
part
mice
imag
show
enter
tumor
tissu
hour
fluoresc
intens
within
tumor
weaken
indic
metabol
hour
hour
strong
fluoresc
signal
urethr
open
nude
mice
indic
circul
bodi
enter
bladder
kidney
excret
form
urin
use
strong
fluoresc
signal
observ
tumor
site
cervic
lymph
node
near
tumor
hour
indic
larg
distribut
fluoresc
signal
part
mice
weak
indic
distribut
tumorbear
nude
mice
regular
hour
fluoresc
signal
still
appear
tumor
site
fluoresc
intens
stronger
tissu
bodi
time
almost
fluoresc
appear
tumor
site
group
indic
metabol
slower
glycosyl
induc
structur
chang
conjug
polysaccharid
chain
increas
steric
hindranc
conjug
improv
drug
abil
resist
hydrolysi
hydrolas
enzym
make
stabl
blood
therebi
demonstr
glycosyl
modif
prolong
stabil
drug
bodi
fluoresc
intens
glycosyl
compound
tumor
site
stronger
polypeptid
group
demonstr
cs
certain
abil
target
tumor
tissu
nude
mice
consist
spr
experiment
result
blood
sampl
collect
predetermin
time
point
balbc
mice
process
fluoresc
intens
measur
concentr
drug
plasma
calcul
pharmacokinet
time
curv
mice
treat
present
figur
plasma
concentr
modifi
glycosyl
lower
lowest
limit
quantit
hour
administr
detect
plasma
hour
plasma
concentr
glycosyl
product
lower
group
hour
plasma
concentr
higher
time
point
tabl
compar
unmodifi
halflif
averag
resid
time
glycosylationmodifi
product
significantli
prolong
clearanc
rate
decreas
vivo
also
found
peak
concentr
two
drug
similar
thu
plasma
concentr
mice
increas
mainten
high
plasma
concentr
long
time
expect
reduc
dosag
frequenc
administr
clinic
applic
solidphas
synthesi
method
extens
use
field
proteinpeptid
drug
research
synthes
polypeptid
method
quickli
accur
synthes
design
target
peptid
chain
product
synthes
quickli
accur
purifi
identifi
hplc
ms
studi
polypeptid
success
synthes
method
puriti
molecular
weight
result
indic
polypeptid
synthes
solidphas
method
peptid
use
futur
studi
activ
peptid
inhibit
endotheli
cell
prolifer
peptid
deriv
es
sequenc
amino
acid
posit
three
time
activ
es
sequenc
directli
block
tyrosin
phosphoryl
vegf
receptor
endotheli
cell
surfac
therebi
block
transmiss
vegfmedi
signal
pathway
addit
studi
specul
nucleolin
may
potenti
receptor
nucleu
endotheli
cell
enter
endotheli
cell
fragment
inhibit
phosphoryl
process
nucleolu
directli
affect
biosynthesi
matur
ribosom
indirectli
influenc
process
chromatin
replic
nucleogenesi
mitot
process
endotheli
cell
arrest
inhibit
endotheli
cell
prolifer
mtt
assay
use
evalu
inhibitori
effect
glycosyl
modif
product
prolifer
cell
found
inhibitori
activ
drug
dosedepend
activ
polypeptid
drug
often
relat
structur
compar
small
molecul
drug
polypeptid
drug
tend
poor
stabil
aqueou
solut
due
spatial
structur
peptid
modifi
cs
stabil
modifi
product
improv
aqueou
solut
cs
increas
solubl
aqueou
solut
cs
group
forc
water
molecul
around
polypeptid
improv
stabil
moreov
higher
concentr
stabil
previou
research
also
support
conclus
addit
mtt
result
also
relat
cell
statu
degre
differenti
cell
better
statu
select
experi
studi
shown
es
could
stabli
bind
precursor
protein
matrix
metalloproteinas
form
complex
block
activ
catalyt
abil
matrix
metalloproteinas
wherea
matrix
metalloproteinas
could
creat
necessari
condit
cell
migrat
dissolv
extravascular
matrix
main
activ
fragment
es
also
abil
stabli
bind
precursor
protein
matrix
metalloproteinas
result
cell
metastasi
show
activ
inhibit
cell
metastasi
significantli
better
unmodifi
low
concentr
signific
differ
high
concentr
agreement
result
mtt
effici
cs
improv
solubl
increas
low
drug
concentr
therefor
effici
inhibit
endotheli
cell
metastasi
concentr
increas
activ
two
drug
equival
might
due
cs
promot
adhes
growth
endotheli
cell
counteract
inhibit
certain
degre
endotheli
cell
prolifer
differenti
vital
part
neovascular
matrigel
solubl
basement
membran
matrix
similar
mammalian
cell
basement
membran
compon
relat
studi
shown
matrigel
extracellular
mechan
complex
ad
cell
cultur
environ
could
promot
cell
prolifer
differenti
collagen
secret
note
mice
receiv
singl
intraven
inject
dose
mgkg
result
shown
mean
sd
abbrevi
c
max
maximum
plasma
concentr
halflif
plasma
mrt
averag
resid
time
vivo
max
time
reach
maximum
plasma
concentr
auc
area
curv
plasma
concentr
versu
time
curv
submit
manuscript
wwwdovepresscom
xing
et
al
mechan
es
inhibit
endotheli
cell
tube
format
similar
inhibit
endotheli
cell
migrat
time
endotheli
cell
migrat
tube
format
continu
process
es
disrupt
integr
microfila
therebi
disrupt
normal
adhes
endotheli
cell
endotheli
cell
matrix
ultim
growth
endotheli
cell
limit
format
vessel
block
cam
model
wide
use
angiogen
model
due
mani
advantag
cost
effect
short
experi
period
high
reproduc
easi
handl
experi
normal
salin
use
control
group
small
amount
bfgf
ad
group
bfgf
induc
factor
vascular
growth
make
result
neovascular
obviou
result
show
activ
highconcentr
group
better
could
stabil
better
howev
compar
result
mixtur
group
peptid
group
low
concentr
condit
found
ad
cs
mixtur
effect
activ
peptid
could
increas
activ
mixtur
also
found
activ
conjug
group
slightli
lower
peptid
group
concentr
phenomenon
may
due
fact
cs
conjug
could
form
gellik
barrier
structur
near
lower
concentr
therefor
conjug
mixtur
group
inferior
activ
low
concentr
pathway
import
signal
pathway
regul
prolifer
divis
migrat
vascular
endotheli
cell
endotheli
cell
regul
begin
signal
inhibit
bind
vegf
receptor
therebi
induc
endotheli
cell
apoptosi
migrat
inhibit
thu
reduc
format
vessel
tumor
tissu
studi
main
activ
fragment
inhibit
bind
vegf
receptor
short
peptid
af
section
water
solubl
af
poor
due
high
content
aromat
amino
acid
therefor
af
modifi
peptid
solidphas
synthesi
improv
water
solubl
modifi
cs
better
watersolubl
mucopolysaccharid
improv
watersolubl
water
solubl
af
significantli
improv
modif
abil
inhibit
bind
vegf
receptor
stronger
present
method
commonli
use
detect
drug
activ
includ
cell
screen
method
biochem
screen
method
compar
cell
screen
method
biochem
screen
method
wide
use
rapid
simpl
effici
spr
method
one
wide
use
biochem
screen
method
realtim
fast
highflux
method
requir
special
mark
techniqu
util
principl
physic
optic
studi
interact
two
molecul
one
molecul
fix
surfac
sensor
sheet
solut
anoth
molecul
flow
surfac
combin
two
molecul
chang
refract
index
sensor
surfac
interact
two
molecul
detect
protein
often
express
malign
highli
metastat
tumor
cell
prognosi
tumor
satisfactori
chemotherapi
relat
studi
shown
close
relat
invas
metastasi
mani
malign
tumor
cell
protein
could
detect
variou
tumor
cell
gastric
carcinoma
glioma
breast
cancer
pancreat
cancer
thu
use
target
tumor
therapi
therapeut
efficaci
tumor
improv
design
drug
target
receptor
spr
studi
ph
valu
suitabl
protein
solut
screen
ensur
coupl
protein
chip
facilit
screen
drug
next
step
ligand
protein
coupl
chip
surfac
necessari
dissolv
protein
buffer
solut
ph
lower
isoelectr
point
higher
ph
protein
surfac
posit
charg
carboxyl
group
neg
charg
chip
surfac
combin
electrostat
adsorpt
isoelectr
point
ph
optimum
ph
valu
protein
solut
screen
sampl
dissolv
pb
buffer
dilut
run
buffer
mm
phosphat
mm
sodium
chlorid
volvol
tween
ph
differ
concentr
sampl
flow
surfac
chip
immobil
receptor
protein
k
valu
obtain
biacor
gener
valu
kd
rang
meant
sampl
strong
affin
ligand
protein
cs
ligand
receptor
specif
bind
receptor
stronger
affin
toward
receptor
unmodifi
therefor
cs
use
modifi
improv
target
drug
tumor
tissu
vivo
imag
new
technolog
qualit
quantit
analyz
distribut
metabol
xing
et
al
drug
live
bodi
use
variou
imag
mode
cellular
molecular
level
compar
tradit
vitro
imag
techniqu
slice
observ
vivo
imag
better
first
obtain
multipl
data
anim
help
elimin
individu
differ
second
continu
observ
period
time
dynam
experiment
result
intuit
drug
distribut
imag
obtain
experiment
result
seen
glanc
final
noninvas
painless
detect
technolog
biolog
behavior
vivo
compli
requir
experiment
ethic
therefor
small
anim
vivo
imag
technolog
wide
use
field
oncolog
research
mani
substanc
organ
produc
fluoresc
skin
hair
rat
food
nude
mice
select
experiment
anim
fast
h
experi
background
nois
remov
attenu
photograph
nude
mice
administr
compar
distribut
metabol
peptid
modif
tumorbear
nude
mice
found
glycosylationmodifi
product
longer
metabol
time
nude
mice
might
glycosyl
modif
chang
structur
conjug
increas
steric
hindranc
thu
improv
abil
resist
hydrolysi
hydrolas
glycosyl
also
increas
stabil
conjug
blood
fluoresc
intens
glycosylationmodifi
product
tumor
site
stronger
polypeptid
group
demonstr
abil
cs
target
tumor
tissu
consist
spr
result
protein
peptid
drug
affect
mani
factor
pharmacokinet
studi
compar
small
molecul
chemic
one
hand
sensit
analyt
method
issu
sinc
dosag
polypeptid
drug
small
hand
amino
acid
polypeptid
drug
suscept
endogen
substanc
organ
often
natur
amino
acid
therefor
requir
distinguish
amino
acid
endogen
substanc
exogen
polypeptid
drug
analysi
process
pharmacokinet
studi
peptid
drug
sever
commonli
use
method
includ
isotop
tracer
method
elisa
liquid
chromatographymass
spectrometri
lcm
fluoresc
label
present
us
fda
use
pharmacokinet
data
obtain
radioisotop
determin
peptid
drug
effect
evalu
safeti
drug
howev
polypeptid
label
radioisotop
prone
label
offlabel
experi
unabl
accur
reflect
concentr
polypeptid
drug
measur
radioact
method
also
shortcom
radioact
contamin
thu
limit
applic
clinic
pharmacokinet
research
although
elisa
method
simpl
conveni
oper
necessari
develop
relat
antibodyco
kit
prepar
period
kit
long
suscept
interfer
biolog
endogen
exogen
substanc
measur
process
lcm
advantag
good
specif
high
sensit
howev
plasma
sampl
contain
larg
amount
salt
endogen
protein
may
interfer
measur
process
fluoresc
label
use
increas
number
peopl
mild
reaction
condit
simpl
detect
method
new
antiangiogen
peptid
prepar
solidphas
synthesi
technolog
light
absorpt
chromogen
group
directli
determin
spectroscopi
chromatographi
common
fluoresc
marker
fitc
due
mild
label
reaction
condit
often
use
label
polysaccharid
polypeptid
studi
pharmacokinet
process
anim
studi
fitc
use
label
fitc
could
link
sever
amino
acid
peptid
chain
dialysi
free
fitc
remov
sampl
prepar
enhanc
fluoresc
intens
sampl
sd
solut
use
fluoresc
sensit
addit
sd
could
produc
larg
amount
premicel
sampl
system
due
fitclabel
molecul
dispers
adher
micel
system
collis
energi
loss
fluoresc
molecul
reduc
quench
effect
oxygen
reduc
absorpt
interfac
fluoresc
group
increas
fluoresc
sensit
sd
solut
brought
order
fluorophor
microenviron
biolog
sampl
reduc
competit
nonradi
deactiv
fluoresc
quench
process
system
improv
quantum
yield
fluoresc
manifest
increas
fluoresc
intens
sampl
among
pharmacokinet
paramet
obtain
studi
clearanc
rate
vivo
halflif
mice
three
time
reason
phenomenon
might
fluoresc
intens
fitc
repres
concentr
studi
metabol
fitc
complet
synchron
vivo
free
fitc
might
coexist
mous
plasma
affect
determin
result
blood
sampl
taken
sever
mice
time
point
individu
differ
mice
led
inconsist
pharmacokinet
paramet
conclud
synthes
solidphas
method
studi
obtain
chemic
modif
new
peptid
cs
first
hnmr
spectrum
show
cs
success
bound
two
peptid
per
one
cs
chain
vitro
activ
studi
result
show
better
abil
inhibit
prolifer
metastasi
endotheli
cell
bind
abil
vitro
vivo
studi
elisa
result
show
glycosylationmodifi
product
inhibit
bind
abil
vegf
receptor
better
peptid
spr
result
show
bind
abil
receptor
better
vivo
imag
experi
show
distribut
tumorbear
nude
mice
target
addit
bioimag
result
show
longer
metabol
time
compar
vivo
may
due
increas
stabil
plasma
consist
vivo
halflif
experi
halflif
approxim
threefold
longer
data
strongli
suggest
cs
desir
effect
extend
halflif
peptid
drug
conclus
modifi
cs
improv
antineovascular
activ
vitro
vivo
enhanc
bind
abil
differ
receptor
vitro
vivo
target
tumor
tissu
significantli
prolong
halflif
mice
result
studi
laid
experiment
foundat
develop
target
antitumor
polypeptid
drug
